Oric Pharmaceuticals (ORIC) to Release Earnings on Monday

Oric Pharmaceuticals (NASDAQ:ORIC) is projected to release its Q1 2026 results before the market opens on Monday, May 4th. Analysts expect Oric Pharmaceuticals to post earnings of ($0.31) per share for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 4:00 PM ET.

Oric Pharmaceuticals (NASDAQ:ORIC) last released its earnings results on Monday, February 23rd. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.04. On average, analysts expect Oric Pharmaceuticals to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Oric Pharmaceuticals Price Performance

ORIC opened at $10.24 on Monday. The company’s 50 day simple moving average is $11.32 and its two-hundred day simple moving average is $11.13. Oric Pharmaceuticals has a 1-year low of $4.52 and a 1-year high of $14.93. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of -6.74 and a beta of 1.36.

Insider Buying and Selling

In related news, CFO Dominic Piscitelli sold 52,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $13.51, for a total value of $702,520.00. Following the transaction, the chief financial officer directly owned 68,148 shares in the company, valued at approximately $920,679.48. This represents a 43.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 5.55% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Corient Private Wealth LLC acquired a new position in Oric Pharmaceuticals in the fourth quarter valued at approximately $102,000. Invesco Ltd. lifted its position in Oric Pharmaceuticals by 19.8% in the fourth quarter. Invesco Ltd. now owns 109,742 shares of the company’s stock valued at $898,000 after buying an additional 18,128 shares during the last quarter. XTX Topco Ltd acquired a new position in Oric Pharmaceuticals in the fourth quarter valued at about $904,000. VARCOV Co. acquired a new position in Oric Pharmaceuticals in the fourth quarter valued at about $262,000. Finally, Virtus Investment Advisers LLC lifted its position in Oric Pharmaceuticals by 141.0% in the fourth quarter. Virtus Investment Advisers LLC now owns 28,361 shares of the company’s stock valued at $232,000 after buying an additional 16,594 shares during the last quarter. 95.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ORIC. Wedbush decreased their target price on shares of Oric Pharmaceuticals from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 1st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Oric Pharmaceuticals in a report on Monday, March 9th. Citigroup lifted their price target on Oric Pharmaceuticals from $16.00 to $17.00 and gave the stock a “buy” rating in a report on Tuesday, February 24th. Piper Sandler started coverage on Oric Pharmaceuticals in a report on Wednesday, January 7th. They set an “overweight” rating and a $22.00 price target on the stock. Finally, Oppenheimer reiterated an “outperform” rating and set a $15.00 price target on shares of Oric Pharmaceuticals in a report on Tuesday, February 24th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $19.90.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.